过去十年，随着多学科治疗的实施，食管癌患者的预后有所改善。目前还没有针对食管癌多学科治疗的综合指南，其中纳入了外科医生、放射肿瘤学家和肿瘤内科医生的意见。为了满足食管癌治疗中多学科投入的需求并满足当前临床实践指南的最佳实践，当前的指南是由胸外科医生协会 (STS) 和美国放射肿瘤学会 (ASTRO) 合作制定的、以及美国临床肿瘤学会 (ASCO)。医生代表选择了与局部晚期可切除胸段食管癌（不包括宫颈部位）患者的护理相关的 8 个关键临床问题。我们进行了全面的文献综述，确定了 227 篇符合纳入标准的文章，涵盖诱导化疗的使用、术前化疗与放化疗的比较、最佳放射剂量、食管切除术的价值、食管切除术的时机、淋巴结清扫术的方法和范围、微创食管切除术以及切除后辅助治疗的价值。相关数据由 80% 的作者组成的专家小组进行审查和投票，其中 75% 的人对证据的类别和水平达成一致。然后将这些数据编入指南文件。版权所有 © 2023 美国放射肿瘤学会、胸外科医师学会。由爱思唯尔公司出版。保留所有权利。

Outcomes for patients with esophageal cancer have improved over the last decade with the implementation of multimodality therapy. There are currently no comprehensive guidelines addressing multidisciplinary management of esophageal cancer that have incorporated the input of surgeons, radiation oncologists, and medical oncologists. To address the need for multidisciplinary input in the management of esophageal cancer and to meet current best practices for clinical practice guidelines, the current guidelines were created as a collaboration between The Society of Thoracic Surgeons (STS), American Society for Radiation Oncology (ASTRO), and the American Society of Clinical Oncology (ASCO). Physician representatives chose 8 key clinical questions pertinent to the care of patients with locally advanced, resectable thoracic esophageal cancer (excluding cervical location). A comprehensive literature review was performed identifying 227 articles that met the inclusion criteria covering the use of induction chemotherapy, chemotherapy vs chemoradiotherapy before surgery, optimal radiation dose, the value of esophagectomy, timing of esophagectomy, the approach and extent of lymphadenectomy, the use of minimally invasive esophagectomy, and the value of adjuvant therapy after resection. The relevant data were reviewed and voted on by the panel with 80% of the authors, with 75% agreement on class and level of evidence. These data were then complied into the guidelines document.Copyright © 2023 American Society for Radiation Oncology, The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.